Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)

Carla L. Alves; Sidse Ehmsen; Mikkel G. Terp; Neil Portman; Martina Tuttolomondo; Odd L. Gammelgaard; Monique F. Hundebøl; Kamila Kaminska; Lene E. Johansen; Martin Bak; Gabriella Honeth; Ana Bosch; Elgene Lim; Henrik J. Ditzel

doi:10.1038/s41467-021-25901-z

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)

Carla L. Alves^*, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › Research › peer-review

10 Downloads (Pure)

Abstract

The original HTML version of this Article was updated shortly after publication because the previous HTML version linked to an incorrect Transparent Peer Review file.

Original language	English
Article number	5588
Journal	Nature Communications
Volume	12
Number of pages	1
ISSN	2041-1723
DOIs	https://doi.org/10.1038/s41467-021-25901-z
Publication status	Published - 16. Sept 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Documents & Links

10.1038/s41467-021-25901-zLicence: CC BY

Open Access VersionFinal published version, 435 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)'. Together they form a unique fingerprint.

Cite this

Alves, C. L., Ehmsen, S., Terp, M. G., Portman, N., Tuttolomondo, M., Gammelgaard, O. L., Hundebøl, M. F., Kaminska, K., Johansen, L. E., Bak, M., Honeth, G., Bosch, A., Lim, E., & Ditzel, H. J. (2021). Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9). Nature Communications, 12, [5588]. https://doi.org/10.1038/s41467-021-25901-z

@article{286977a2bf68450ba6eccf4e8124a278,

title = "Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)",

abstract = "The original HTML version of this Article was updated shortly after publication because the previous HTML version linked to an incorrect Transparent Peer Review file.",

author = "Alves, {Carla L.} and Sidse Ehmsen and Terp, {Mikkel G.} and Neil Portman and Martina Tuttolomondo and Gammelgaard, {Odd L.} and Hundeb{\o}l, {Monique F.} and Kamila Kaminska and Johansen, {Lene E.} and Martin Bak and Gabriella Honeth and Ana Bosch and Elgene Lim and Ditzel, {Henrik J.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = sep,

day = "16",

doi = "10.1038/s41467-021-25901-z",

language = "English",

volume = "12",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

}

Alves, CL , Ehmsen, S , Terp, MG, Portman, N, Tuttolomondo, M , Gammelgaard, OL, Hundebøl, MF, Kaminska, K, Johansen, LE, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, HJ 2021, 'Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)', Nature Communications, vol. 12, 5588. https://doi.org/10.1038/s41467-021-25901-z

Publisher Correction : Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9). / Alves, Carla L.; Ehmsen, Sidse ; Terp, Mikkel G. et al.

In: Nature Communications, Vol. 12, 5588, 16.09.2021.

Research output: Contribution to journal › Comment/debate › Research › peer-review

TY - JOUR

T1 - Publisher Correction

T2 - Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)

AU - Alves, Carla L.

AU - Ehmsen, Sidse

AU - Terp, Mikkel G.

AU - Portman, Neil

AU - Tuttolomondo, Martina

AU - Gammelgaard, Odd L.

AU - Hundebøl, Monique F.

AU - Kaminska, Kamila

AU - Johansen, Lene E.

AU - Bak, Martin

AU - Honeth, Gabriella

AU - Bosch, Ana

AU - Lim, Elgene

AU - Ditzel, Henrik J.

PY - 2021/9/16

Y1 - 2021/9/16

N2 - The original HTML version of this Article was updated shortly after publication because the previous HTML version linked to an incorrect Transparent Peer Review file.

AB - The original HTML version of this Article was updated shortly after publication because the previous HTML version linked to an incorrect Transparent Peer Review file.

U2 - 10.1038/s41467-021-25901-z

DO - 10.1038/s41467-021-25901-z

M3 - Comment/debate

C2 - 34531405

AN - SCOPUS:85115390408

SN - 2041-1723

VL - 12

JO - Nature Communications

JF - Nature Communications

M1 - 5588

ER -

Alves CL , Ehmsen S , Terp MG, Portman N, Tuttolomondo M , Gammelgaard OL et al. Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9). Nature Communications. 2021 Sept 16;12:5588. Epub 2021 Sept 16. doi: 10.1038/s41467-021-25901-z